Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery Platform
Sponsor : GSK
Deal Size : $1,150.0 million
Deal Type : Collaboration
Details : The collaboration will combine Adrestia’s world leading, synthetic viability platform with GSK’s deep scientific expertise in human genetics, functional genomics, screening, and bioinformatics.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 18, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery Platform
Sponsor : GSK
Deal Size : $1,150.0 million
Deal Type : Collaboration
Reset All
